| Literature DB >> 25487828 |
Priyanka Kapoor, Om Prakash Kharbanda1, Nitika Monga, Ragini Miglani, Sunil Kapila.
Abstract
This systematic review aimed to generate evidence on role of potent markers of inflammation [cytokines, chemokines, their associated receptors and antagonists] following the application of orthodontic forces. Subsequent to registration with PROSPERO, literature search followed a predetermined search strategy to key databases along with hand search (HS). Seventy-seven articles from PubMed (P), 637 from Scopus (S), 51 from Embase (E), and 3 from hand search (HS) were identified. A total of 39 articles were shortlisted that met strict inclusion and exclusion criteria and quality assessment. Each study was evaluated for participant characteristics, study design, oral hygiene regimen, and gingival crevicular fluid (GCF) handling. Among these studies, biomarkers in the order of frequency were interleukin (IL)-1β (N=21), tumor necrosis factor (TNF)-α (N=10), IL-8,IL-6(N=8), receptor activator of nuclear factor kappa-B ligand (RANKL) (N=7), monocyte chemoattractant protein (MCP)-1 (N=3), IL-2 (N=4), IL-4, IL-10, RANTES (N=2), IL-1, IL-5, IL-1α, IP-10, osteopontin (OPN) (N=1) and receptors and their antagonists in the order of osteoprotegerin (OPG) (N=8), IL-1RA (N=5), and RANK (N=1). Results revealed an immediate release of inflammatory bone-resorptive mediators, IL-1β and TNF-α, where IL-1β increased as early as 1 min to 1 h reaching peak at 24 h while TNF-α increased at 1 h or 1 day. This was accompanied by a fall in bone-protective mediator (OPG) levels at 1 h and 24 h after orthodontic force application. Continuous forces were accompanied by a decrease in mediator levels after attaining peak levels (most commonly at 24 h) while repeated activations in interrupted force upregulated their secretion. Significant correlations of IL-1β levels with pain intensity, rate of orthodontic tooth movement (OTM) and of activity index (AI) (IL-1β/IL-1RA) with velocity of tooth movement and growth status of individuals have also been deduced. A greater AI and RANKL/OPG ratio was seen in juveniles as compared to adults or non-growers that were associated with faster rate of OTM in juveniles. None of the studies addressed the effect of estrous cycle in female subjects. Lack of homogeneity in several parameters calls for a better controlled research on the biology of OTM.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25487828 PMCID: PMC4259981 DOI: 10.1186/s40510-014-0065-6
Source DB: PubMed Journal: Prog Orthod ISSN: 1723-7785 Impact factor: 2.750
Figure 1Flowchart depicting the retrieval of studies for review process.
Participant characteristics
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 22 | 16 | 2 M, 14 F | 18 to 24 y | IL-1β | Mx and Md C | Md R or L C | D | Y | Class I biMx | Y | NM | Y | NM |
| 23 | 22 | 11 M, 11 F | 14.4 + _1.1 y | Leptin | Mx C | Contr C | D | N | Mx 1st PM Extr cs | Y | Y | Y | Y |
| 24 | 33 | 21 M, 12 F | 10.8 to 30.9 y | IL-1β, IL-1RA | Mx C | IP Md C/Aj T | D | y | Mx 1st PM Extr cs | NM | NM | NM | NM |
| 25 | 12 | 7 F, 5 M | 13 to 17 y | OPG | Mx C | Contr C | D | N | Mx 1st PM Extr cs | Y | Y | Y | Y |
| 26 | 9 | 5 M, 4 M | 10 to 18 y | IL-1β, βG | 1st Mo, 1st PM, CI | NM | MP and MB | N | RME cs | NM | NM | NM | NM |
| 27 | 12 SD (6) LD (6) | SD: 3 M, 3 F | SD: 11 to 18 y | IL-1β, −6, IL-8, TNF-α | Mx 1st PM | Ant T | DB | N | Mx 2nd PM Extr cs | Y | Y | Y | Y |
| 28 | 10 | 4 M, 6 F | NM | TNF-α | C | NM | D | N | Mx 1st PM Extr cs | Y | Y | Y | Y |
| 29 | 18 | 9 M, 9 F | 16 to 19 y | IL-1β, −TNF-α | Mx C | NM | M and D | N | 1st PM Extr cs | Y | Y | Y | Y |
| 30 | 30:15 J/15 A | J: 7 M, 9 F | J: 15.1 ± 2.8 y | RANKL, OPG | 1 Mx C | Contr and ant C | D | N | Mx 1st PM Extr cs | Y | Y | Y | Y |
| A: 31 ± 3.6 y | |||||||||||||
| 31 | 15 | 6 M, 9 F | 15 to 19 y | IL-2, IL-6, IL-8 | Mx C | NM | M and D | N | 1st PM Extr cs | Y | Y | Y | Y |
| 32 | 10 | 4 M, 6 F | M −14.5 y | RANKL, OPG | Mx C | Contr and opposing C | D | N | Mx 1st PM Extr cs | Y | Y | Y | Y |
| F 15.4 y | |||||||||||||
| 33 | 18 | 10 M, 8 F | 8.9 to 13.8 y | IL-1β, SP, PGE2 | 1st Mx/Md M | Ant L or R 1st M | DB and DP | N | Crowding in 1 or both jaws | Y | Y | Y | Y |
| 34 | 9 | 3 M, 6 F | M: 21.3 ± 2.8 y | IL-1β, SP | Mx C | Contr C | D | N | Mx 1st PM Extr cs | Y | Y | Y | Y |
| F: 23.1 ± 2.4 y | |||||||||||||
| 35 | 10 | 3 M, 7 F | 10 y 5 m to 30 y 11 m | IL-1β, IL-1RA | R and L Mx C | Md. R C | M and D | Y | Mx 1st PM Extr cs | NM | NM | NM | NM |
| 36 | 10 | NM | 15 to 17 y | IL-8 | Mx and Md C | NM | M and D | 1st PM Extr cs | Y | Y | Y | Y | |
| 37 | 10 | 2 M, 8 F | 18.4 to 22.5 y | IL-1β, PGE2 | Mx C (E1), Contr Mx C (E2) | Ant Md C | D | N | All 1st PM Extr cs | Y | Y | Y | Y |
| 38 | 84 | 43 J (M) | J: 11 ± 0.7 y | PGE-2, IL-6, GMCSF | Mx LI | Contr LI | M and DB | N | Labial tipping reqd | Y | Y | Y | Y |
| 41 A (M) | A: −24 ± 1.6 y | ||||||||||||
| 39 | 9 | 5 M, 4 F | 10 to 18 y | IL-1β βG | 1st Mo, 1st PM, CI | NM | MP and MB | N | RME cs | Y | Y | Y | Y |
| 40 | 7 | 2 M, 5 F | 12 y 3 m to 16 y 3 m | IL-1β, IL-1RA, AI | Mx C | Md C | M and D | NM | All 1st PM Extr | Y | NM | Y | NM |
| 41 | 12 | 3 M, 9 F | 14.4 ± 0.9 y | TGF-β | C | Ant C/Contr C | D | NM | All 1st PM Extr | Y | Y | Y | Y |
| 42 | 12 | 3 M, 9 F | 14.4 ± 0.9 y | IL-1β, IL-6, TNF-α, EGF, β2-μG | C | Ant C/Contr C | D | NM | All 1st PM Extr | Y | Y | Y | Y |
| 19 | 10 | 5 M, 5 F | M: 24.6 ± 1.5 y F: 27.8 ± 3.9 y | IL-1β, PGE | Mx LI, Mx 1st PM | Contr T | MB | N | Buccal/labial OTM | Y | Y | Y | Y |
| 43 | 50 | 23 M, 27 F | 13 to 20 y | IL-1β, TNF-α, NO | Mx I, Mx C | NM | M and D | NM | Non Extr | Y | NM | Y | Y |
| 44 | 10 | 5 M, 5 F | 12 to 16 y | RANKL, OPG | 1st PM (quad 1) | 1st PM (quad 2) | D | NM | 2nd Mx PM Extr | Y | NM | Y | NM |
| 45 | 22 | 7 M, 15 F | 19 to 29 y | HSP70, RANKL | Mx C | Contr C | NM | Mx 1st PM Extr | Y | NM | Y | NM | |
| 46 | 12 | 6 M, 6 F | 11 to 15 y | MMP-8, IL-1β | 1st M, CI, C | NM | M | NM | NM | Y | Y | Y | Y |
| 47 | 21 | NM | 12 to 20 y | GM-CSF, IF-ϒ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10 and TNFα, MMP-9, TIMP-1 and 2, RANKL, OPG | Mx C | 2nd M | MB and DP | NM | Mx 1st PM Extr | Y | Y | Y | Y |
| 48 | 10 | 5 M, 5 F | 22 to 29 y | RANK, OPG, OPN, TGF-β1 | 1st M | Contr M | Exp T: MB and DB Cont T: MB and ML | Y | NM | Y | NM | Y | Y |
| 49 | 14 | 3 M, 11 F | 12 to 28 y | MMP-3, MMP-9, MMP-13, MIP-1β, MCP-1, RANTES | Mx C | NM | M and D | NM | Mx 1st PM Extr | Y | NM | NM | NM |
| 50 | 18 | 8 M, 10 F | 8.9 to 13.8 y | IL-1β, SP, PGE2 | 1st M | Contr M | M and D | NM | Crowding in Mx and Md | Y | Y | Y | Y |
| 51 | 10 | NM | 16.3 ± 2.5 y | IL-1β | Mx C | Md C | DB | NM | Class II, all 1st PM Extr | Y | Y | Y | Y |
| 52 | 16 | 8 M, 8 F | 16.6 ± 2.4 y | IL-2, IL-6, IL-8 | Mx C | Mx 2nd PM | DB | NM | Mx 1st PM Extr | Y | Y | Y | Y |
| 53 | 20 | C: 3 M, 7 F | 18 to 45 y | CCL-2 (MCP1), CCL-3, CCL-5 (RANTES), IL-8 (CXCL8), IL-1α, IL-1β, IL-6, TNF-α | Mx C | Contr C | DB | Y | Class II Div 1 Mal With 1st PM Extr | Y | Y | Y | Y |
| 54 | 16 | 8 M, 8 F | 16.6 ± 2.4 y | TNF-α | Mx C | Mx 2nd PM | DB | NM | Mx 1st PM Extr | Y | Y | Y | Y |
| 55 | 17 | 9 M, 8 F | 16 to 20 y | TNF-α, IL-1β, IL-8 | Mx C | NM | M and D | NM | All 1st PM Extr | Y | Y | Y | Y |
| 56 | 10 | 5 M, 5 F | 15 y ± 3 y 8 m | IL-1β, IL-1RA | Mx C | Md C/Aj t | D | NM | All 1st PM Extr | NM | NM | NM | NM |
| 57 | 20 | 10 ado (3 M, 7 F), 10 A (4 M, 6 F) | Ado: 14.4 ± 1.43 y | RANKL, OPG, IL-1, IL-1RA, MMP-9 | Mx I | Md I | Lab | NM | Non Extr, 3 to 6 mm I crowding | N | N | Y | N |
| 58 | 24 HG-14 NHG-10 | 10 M, 14 F | 14.66 ± 1.1 y | IL-2, IL-4, IL-6, IL-8, IL-10, GM-CSF, IFN-γ, TNFα, MCP-1, IP-10 | Mx 1st M and Mx 1st PM | NM | MB and DB | N | Non extr cs | Y | NM | Y | Y |
| 59 | 9 | 4 M, 5 F | 17.5 to 18.9 y | OPG, RANKL | Mx C | NM | M and D | NM | All 4 Extr | Y | Y | Y | Y |
Ref No. reference number, S sample, M/F male/female, med mediator, T tooth, sp specification, Rnd randomization, Mal malocclusion, HS hand searched, P PubMed, S Scopus, E Embase, N no, Y yes, Mx maxilla, Md mandible, H history, Ls loss, Ging gingival, Inflm inflammation, PD probing depth, NM not mentioned, m month, d day, wk week, h hour, R right, L left, C canine, PM premolar, Mo molar, CI central incisor, Ant antagonistic, Contr contralateral, IP interproximal, oppos opposing, Exp experimental tooth, Cont control tooth, Aj adjacent, E1 experimental site 1, E2 experimental site 2, Extr extraction, M mesial, D distal, Retr retraction, y year, cs cases, IL interleukin, NO nitric oxide, RANKL receptor activator of NFкB ligand, β2-μG β2 microglobulin, TNF tumor necrosis factor, TGF transforming growth factor, EGF epidermal growth factor, SP substance P, PGE prostaglandin, HSP heat shock protein, IFN Interferon, MMP matrix metalloproteinase, TIMP tissue inhibitor of metalloproteinases, MCP monocyte chemoattractant protein, MIP macrophage inflammatory process, RANTES regulated on activation normal T cells expressed and secreted, GM-CSF granulocyte-macrophage colony-stimulating factor, reqd required, quad quadrant, OTM orthodontic tooth movement, Lab labial surface, ado adolescent, J juveniles, A Adults.
Study characteristics
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|
| 22. | 50 and 150 g | Cont F | Retr- se | Ni-Ti spg | N | 2 m | 6 | 0, 1, 24 h, 1 wk, 1 m, 2 m | 0 | N |
| 23. | 250 g | Intrrup F | Retr- se | E-chain | NM | 168 h | 4 | 0, 1 h, 24 h, 168 h | 0 | N |
| 24 | 4, 13, 26, 52, or 78 kPa | Cont F | Retr- se | Vert loop act. with Ni-Ti spg | N | 84 d | 9 to 10 | 0, 1, 3, ±7, 14, 28, 42, 56, 70, 84 d | 0 | N |
| 25 | 150 g | Cont F | Retr- se | Ni-Ti spg | N | 3 m | 6 | before act 0, after act 1 h, 24 h, 168 h, 1 m, 3 m | 0 | N |
| 26 | NM | Interm F | Mx expans | Hyrax screw | Y | 81 d | 10 | 0, 14, 25, 32, 33, 39, 46, 53, 60, 81 d | 14 d | Y |
| 27 | SD-NM LD-50 cN | SD - intrrup F LD - cont F | SD - space gaining LD - Retr- se | SD-E - separt LD - Ni-Ti spg | N | SD - 24 h LD - 4 m | SD - 2 LD - 5 | SD - 0 h, 24 h LD - 0, T1, 1 m, 2 m, 3 m | 0 | N |
| 28 | HG - RDG-NM | HG - cont F RDG - heavy Intrrup F | Retr- se | HG - hybrid retract RDG - C distalizer | HG-N RDG-Y | 1 wk | 4 | Before act (0), after act 1 h, 24 h, 1 wk | 0 | Y |
| 29 | Level-NS | Cont F | Level Retr- se | 0.014” NiTi wire | N | 6 m 21 d | 7 | Level - 0, 7 d, 21 d, 3 m | Level - 0 | Y |
| Retr - 150 g | Cont F | |||||||||
| 30 | 250 g | Intrrup F | Retr- se | E-chain | NM | 168 h | 4 | 0, 1, 24, 168 h | 0 | N |
| 31 | Level-NS | Cont F | Level Retr- se | 0.014” NiTi wire | NM | 6 m 21 d | 6 | Level - 0, 7 d, 21 d | Level - 0 | Y |
| Retr - 150 g | Cont F | |||||||||
| 32 | 250 g | Intrrup F | Retr- se | E-chain | N | 7 d | 4 | 0, 1, 24, 168 h | 0 | N |
| 33 | NM | Intrrup F | Space gaining | E - separt | N | 14 d | 5 | −7 d, 0 d, 1 h, 1 d, 7 d | 0 | N |
| 34 | 250 g | Intrrup F | Retr- se | E-chain | N | 168 h | 8 | 0, 1, 4, 8, 24, 72, 120, 168 h | 0 | N |
| 35 | 60, 18, 120, 240 g | Cont F | Retr- se | Vert loop act. with Ni-Ti spg | N | 112 d | 11 | −28, −14, 0, 1, 3, 14, 28, 42, 56, 70, 84 d | 0 | N |
| 36 | Mx C - 115 g | Cont F | Retr- se | Ricketts seg arch | N | 30 d | 6 | 0, 1 h, 24 h, 6 d, 10 d, 30 d | 0 | Y |
| Md C - 90 g | ||||||||||
| 37 | E1: 100 g | E1: Cont | Retr | E1: NiTi spg | E1: N | 3 wk | 10 | 0, 1 h, 24 h, 1 wk, repeat twice | 0 | N |
| E2: NM | E2: Intrrup | E2: screw attached retractor | E2: 2 | |||||||
| 38 | 70 cN | Cont | Tipping | bu/la offset | N | 24 h | 2 | 0, 24 h | 0 | N |
| 39 | NM | Interm F | Mx expans | Hyrax screw | Y | 81 d | 11 | 0, 14, 18, 25, 32, 33, 39, 46, 53, 60, 81 d | 0 | Y |
| 40 | 13 to 4 kPa | Cont | Retr | V loop act by spg | N | 84 d | 9 | 0, 1, 3 d, 14 d intervals until 84 d | 0 | N |
| 41 | 2 to 2.5 N | Intrrup | Retr | E-chain | N | 7 d | 4 | 0, 1, 24, 168 h | 0 | N |
| 42 | 250 g | Intrrup | Retr | E-chain | N | 7 d | 4 | 0, 1, 24, 168 h | 0 | N |
| 19 | 100 g | Cont | Labial tipping | La offset in NiTi wire | N | 7 d | 5 | 0, 1, 24, 48, 168 h | 0 | N |
| 43 | NM | NM | NM | Alignment | NM | 6 m | 3 | 0, 1 m, 6 m | 0 | N |
| 44 | 150 g | Cont | Retr | NiTi spg | N | 45 d | 6 | 0, 2, 4, 7, 30, 45 d | 0 | N |
| 45 | 130 g | Intrrup | Retr | E-chain | N | 24 h | 2 | 0, 24 h | 0 | N |
| 46 | NM | NM | NM | Bracket placement | N | 3 m | 4 | 0, 24 h, 1 wk, 3 m | 0 | Y |
| 47 | 100 g | Cont | Retr | NiTi c.c. spg | N | 42 d | 4 | −10 wk, 0, 4 h, 7 d, 42 d | 0 | N |
| 48 | NM | Intrrup | Space gain | Elastic separt | N | 7 d | 3 | 0, 24 h, 7 d | 0 | N |
| 49 | 150 g | Cont | Retr | V - loop and NiTi c.c. spg | N | 87 d | 7 | −7 d, 0, 1 h, 24 h, 14, 21, 80 d | 0 | Y |
| 50 | NM | Intrrup | Space gin | Elastic separt | N | 14 d | 6 | −7 d, 0, 1 min, 1 h, 1 d, 7 d | 0 | N |
| 51 | 120 g | Cont | Retr | NiTi c.c. spg | N | 21 d | 6 | 1 h, 24 h, 48 h, 168 h, 14 d, 21 d | 1 h | N |
| 52 | 150 g | Cont | Retr | Sentalloy c.c. spg | N | 3 m | 7 | 0, 1, 24, 48 h, 7 d, 21 d, 3 m | 0 | N |
| 53 | 100 g | Cont F | Retr- se | Ni-Ti c.c. spg | N | 28 d | 4 | 0, 1 d, 7 d, 28 d | 0 | Y |
| 54 | 150 g | Cont | Retr | Sentalloy c.c. spg | N | 3 m | 7 | 0, 1, 24, 48 h, 7 d, 21 d, 3 m | 0 | N |
| 55 | NM | Cont | Alignment | 0.014 NiTi wire | N | 7 d | 8 | 0, 1, 2, 3, 4, 5, 6, 7 d | 0 | Y |
| 56 | 13, 26, 52 kPa | Cont | Retr | V loop act by spg | N | 84 d | 9 | 0, 1, 3 d, 14 d intervals until 84 d | 0 | N |
| 57 | NM | Cont | Alignment | 0.014 - NiTi, 0.016 × 0.022 NiTi, 0.019 × 0.025 NiTi | N | 20 wk | 6 | 0, 3 wk, 6 wk, 12 wk, 2 wk | 0 | N |
| 58 | NM | HG: band intrrup F Bond - Cont F NHG - Cont F | Level | 0.014 - in NiTi wire 0.016 × 0.022-in s.s. | N | 70 wk | HG: band-3 HG; bond-2 NHG-2 | HG: band - 18, 0, 52 wk | HG: band - 18 wk | Y |
| HG: bond - 0, 52 wk | Bond - 0 wk | |||||||||
| NHG - 0, 52 wk | NHG - 0 wk | |||||||||
| 59 | 200 g | Cont | Retr | Sentalloy c.c. spg | N | 1 m | 5 | 0,1 h, 24 h, 168 h, 1 m | 0 | Y |
Ref No. reference number, F force, T/O type of, Mech mechanics, Mech/O mechanics of, appli appliance, React reactivation, Tot total, Du duration, N number, obs observation, Bas baseline, min minutes, g grams, Intrrup interrupted, Cont continuous, interm intermittent, Retr retraction, se segmented, spg spring, E-chain elastomeric chain, NiTi nitinol, cont control, NM not mentioned, y year, d day, m month, h hour, Level leveling, separt separator, act activated, HG headgear, NHG non-headgear, bu buccal, la labial, HG hybrid retract, RDG rapid canine distalizer.
Oral hygiene regimen and assessment of gingival health
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|
| 22 | Chlorhex | Twice | NM | NM | Y | Y |
| 23 | N | NA | Y | Y | Y | At 0 and 168 h |
| 24 | NM | NM | Y | Y | Y | Y |
| 25 | NM | NA | Y | Y | N | N |
| 26 | Chlorhex | Twice | Y | NM | Y | Y |
| 27 | Chlorhex | Twice | Y | Y | Y | Y |
| 28 | NM | NA | NM | NM | Y | NM |
| 29 | NM | NA | NM | NM | NM | NM |
| 30 | NM | NA | Y | Y | Y | Y |
| 31 | NM | NA | NM | NM | NM | NM |
| 32 | NM | NA | Y | Y | Y | Y |
| 33 | Chlorhex | Twice | Y | Y | Y | Y |
| 34 | NM | NA | Y | Y | Y | Y |
| 35 | Chlorhex | Twice | Y | Y | Y | Y |
| 36 | NM | NM | Y | Y | Y | Y |
| 37 | NM | NM | NM | NM | Y | Y |
| 38 | NM | NM | Y | Y | NM | NM |
| 39 | Chlorhex | Twice | Y | NM | Y | Y |
| 40 | Chlorhex | Twice | Y | Y | Y | Y |
| 41 | NM | NM | NM | NM | Y | Y |
| 42 | NM | NM | NM | NM | Y | Y |
| 19 | Chlorhex | NM | NM | NM | Y | |
| 43 | NM | NM | Y | Y | Y | Y |
| 44 | Chlorhex | Twice | Y | Y | Y | Y |
| 45 | NM | NM | Y | Y | NM | NM |
| 46 | NM | NM | Y | Y (6 wk, 3 m) | Y | Y |
| 47 | NM | NM | NM | NM | Y | Y |
| 48 | NM | NM | Y | Y | Y | Y |
| 49 | Chlorhex | Twice | Y | Y | NM | NM |
| 50 | NM | NM | Y | N | Y | Y |
| 51 | NM | NM | NM | NM | NM | NM |
| 52 | NM | NM | Y | Y | Y | NM |
| 53 | NM | NM | Y | Y | Y | NM |
| 54 | NM | NM | Y | Y | Y | NM |
| 55 | NM | NM | NM | NM | NM | NM |
| 56 | Chlorhex | Twice | Y | Y | Y | Y |
| 57 | NM | Y | NM | NM | NM | |
| 58 | NM | NA | Y | NM | Y | Y |
| 59 | NM | Y | Y | Y | Y |
Ref No. reference number, Mu mouth, wsh wash, Freq/O frequency of, d day, prophy prophylaxis, t/t treatment, obser observation, pt point, Asses assessment, ging gingival, perio periodontal, inflam inflammation, chlorhex chlorhexidine, Y yes, NM not mentioned, N no, h hour.
GCF characteristics
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 22 | NM | NM | NM | D | 1 mm | 2 | 90 s | PP | 30 s | −80°C | PT8000 | ELISA | pg/mg |
| 23 | Y | NM | NM | D | 1 mm | 4 | 60 s | PP | 30 s | −80°C | PT8000 | ELISA | pg/ml |
| 24 | NM | NM | NM | D | NM | 2 | NM | NM | NM | NM | NM | ELISA | NM |
| 25 | NM | NM | NM | D | 1 mm | N | NA | PP | 30 s | −80°C | PT8000 | ELISA | pg/μl |
| 26 | NM | Y | Y | M | NM | N | NA | PP | 30 s | NM | PT6000 | ELISA | pg/30 s |
| 27 | NM | NM | NM | DB | 1 mm | N | NA | PP | 30 s | −20°C | PT8000 | MB-IA | pg/μl |
| 28 | Y | NM | NM | D | 1 mm | 4 | 60 s | PP | 30 s | −80°C | Elec scale | ELISA | pg/μl |
| 29 | Y | NM | NM | M and D | 1 mm | N | NA | PP | 30 s | −20°C | PT8000 | IA | pg |
| 30 | NM | NM | NM | D | 1 mm | 2 | 60 s | PP | 60 s | −30°C | PT8000 | ELISA | pg/μl |
| 31 | Y | NM | NM | M and D | NM | N | NA | PP | 30 s | −20°C | PT8000 | IA | pg |
| 32 | NM | NM | NM | D | 1 mm | 1 | 60 s | PP | 60 s | −30°C | PT8000 | ELISA | pg/μl |
| 33 | NM | NM | NM | DB and DP | 1 mm | NM | NA | DuFM | 20 s | −70°C | NM | ELISA | pg/20-s samp |
| 34 | NM | NM | NM | D | 1 mm | 2 | NM | PP | 60 s | −30°C | PT8000 | ELISA | pg/μg |
| 35 | NM | NM | NM | M and D | 1 mm | 1 | 60 s | PP | 30 s | −70°C | NM | ELISA | mg/l - tot prot, IL-1-ng/g IL-1RA- μg/g |
| 36 | NM | NM | NM | M and D | 1 mm | 1 | 60 s | PP | 30 s | −70°C | Elect scale | ELISA | pg/ml |
| 37 | Y | Y | Y | D | 1 mm | 4 | 1 min | PP | 30 s | −70°C | NM | ELISA | pg/μg |
| 38 | NM | Y | NM | MB and DB | 1 mm | N | N | PP | 30 s | −80°C | PT6000 | RIA | pg/μl |
| 39 | NM | Y | Y | M | NM | N | NA | PP | 30 s | NM | PT6000 | ELISA | pg/30-s GCF |
| 40 | NM | NM | NM | M and D | 1 mm | 1 | 1 min | PP | 30 s | −70°C | NM | ELISA | Tot prot - mg/l, IL-1β (ng/g), IL-1RA (μg/g) |
| 41 | NM | NM | NM | D | 1 mm | 1 | 1 min | PP | 30 s | −30°C | PT | ELISA, EP, WB | pg/μg |
| 42 | NM | NM | NM | D | 1 mm | 1 | 1 min | PP | 30 s | −30°C | PT | ELISA | pg/μg |
| 19 | Y | Y | y | MB | 1 mm | N | N | PP | 30 s | −80°C | PT6000 | RIA | pg |
| 43 | NM | NM | NM | M and D | NM | NM | NM | PP | 30 s | NM | PT8000 | ELISA | NM |
| 44 | NM | NM | NM | D | NM | N | N | PP | 30 s | −80°C | PT8000 | ELISA | pg/μl |
| 45 | NM | NM | NM | D | 2 mm | 1 | 2 min | PP | 1 min | −20°C | NM | ELISA, WB, SDS-PAGE | NM |
| 46 | NM | NM | NM | M | NM | N | N | FP | 3 min | −30°C | NM | ELISA | IL-1β; pg/ml, MMP-8: ng/ml |
| 47 | NM | NM | NM | MB and DP | NM | N | N | PP | 30 s | NM | PT8000 | LMAT | pg/ml |
| 48 | NM | NM | NM | ExpT: MB and DB | 1 mm | N | N | PP | 30 s | NM | PT8000 | ELISA | Cyt conc - pg/μl |
| 49 | NM | NM | NM | M and D | 1 mm | N | N | PP | NM | −80°C | PT8000 | MB-IA | pg/site |
| 50 | NM | NM | NM | MB and DB | 1 mm | N | N | FM | 20 s | −70°C | NM | ELISA | pg/20 s |
| 51 | Y | Y | Y | DB | NM | N | N | FP | 3 min | −70°C | NM | ELISA | pg/μl |
| 52 | Y | NM | NM | DB | NM | 1 | 1 min | PP | 30 s | −20°C | PT8000 | ELISA | pg/μl |
| 53 | Y | NM | NM | DB | 1 mm | 0 | NA | FP | 10 s | NM | PT8000 | CPA | pg/μl |
| 54 | Y | NM | NM | DB | NM | 1 | 1 min | PP | 30 s | −20°C | PT8000 | IA | pg/μl |
| 55 | Y | NM | NM | NM | 1 mm | N | N | PP | 30 s | −20°C | PT8000 | IA | pg |
| 56 | NM | NM | NM | D | 1 mm | 1 | 1 min | PP | 30 s | −70°C | NM | ELISA | Tot prot - mg/l, IL-1β (ng/g), IL-1RA (μg/g) |
| 57 | NM | NM | NM | DL | 1 mm | N | N | PP | 30 s | −80°C | NM | QAK | pg/ml |
| 58 | NM | NM | NM | MB and DB | NM | 2 | NA | PP | 30 s | −70°C | PT6000 | BHCA | pg/ml |
| 59 | NM | NM | NM | M and D | 1 mm | 1 | 1 min | PP | 30 s | −70°C | Precisa 62 A | ELISA | pmol/l |
Ref No. reference number, Humd humidity, sp specification, Inser insertion, MB mesio-buccal, ML mesio-lingual, DP disto-palatal sites, DB disto-buccal sites, M mesial, D distal, NM not mentioned, N no, Y yes, PP periopaper, PT periotron, FP filter paper strips, FM Durapore filter membrane, WB Western blot, ELISA enzyme linked immune sorbent assay, SDS-PAGE sodium-dodecyl sulfate polyacrylamide gel electrophoresis, RIA radio-IA, I/O interval of, Meth/O method of, coll collection, meas measurement, Du/O duration of, Temp temperature, sto storage, Anal analysis, Prot protein, conc concentration, pg picogram, mg microgram, ml milliliter, μl microliter, GCF gingival crevicular fluid, tot total, g gram, ng nanogram, s seconds, min minutes, °C degree Celsius, elect electronic, IA immunoassay, EP electrophoresis, sP spectrophotometry, Ar array, A assay, MB multiplex bead, LMAT Luminex multianalyte technology, BHCA Bio-Plex human cytokine assay, CPA custom protein array, QAK Quantibody Ar kit, DuFM Durapore filter membrane.
Result characteristics
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|
| 22. | IL-1β | ANOVA and Friedman and paired | Y | NM | Inc | 24 h, 2 m | 1. Mean tot prot conc - 12 mg/ml | C mov with less pain and inflam with 50 g than with 150 g of F | Inc at 24 h and 2 m in 150 g F compd to cont |
| 2. VAS score of 150 g > 50 g at 24 h | |||||||||
| 23. | Leptin | Wilcoxon, Friedman | NM | NM | Dec | 168 h | NM | NM | b/w bas and 168 h in exp T |
| 24 | IL-1β, IL-1RA | ANCOVA | Y | Y | Fluct | NM | For same stress and grw status, max diff in speed were 4.2:1 for 13 kPa in growers and 4.8:1 for 26 kPa in Nn-growers | Higher speeds of T move sign assoc with gen type 2 at IL-1β (+3,954), higher AI, and lower IL-1RA in GCF | NM |
| 25 | OPG | Shapiro Wilk’s Normality, Wilcoxon, Friedman, Z | NM | NM | Dec | NM | NM | NM | Dec at 1 h, 24 h, 168 h, 1 m, 3 m compd with bas |
| 26 | IL-1β, βG | 1-tailed paired Student | Y | NM | Inc | M-010 PM-07 CI-08 | βG sign inc for M - 07 to 010 PM-07,08,010 CI - 06, 07, 010 and dec at O2 for M, PM, CI | Stronger F cause higher levels of both IL-1β and βG | IL-1β sign inc for M - O5 to O10 for PM-O6 to 010. |
| 27 | IL-1β, IL-6, IL-8, TNF-α | Mann-Whitney, Kruskal-Wallis | Y | NM | Inc | SD - 24 h LD - T1 | NM | NM | In SD IL-1β, IL-8, TNF-α inc, In LD inc of IL-8 at T1 |
| 28 | TNF-α | Intergrp - Mann-Whitney U | NM | NM | Inc | 24 h | PI, PD, BOP sign higher in HG GCF vol at 1 h and 24 h in the RDG > HG | NM | HG - a stat sign dec at 1 wk compd to 24 h. |
| 29 | IL-1β,-TNF-α | 1-way paired | NM | NM | Inc | 7 d, 21 d | GCF vol inc on 7 d and 21 d of level and retr | NM | TNF –α diff b/w 3 m (level) and 6 m (bf retr) |
| 30 | RANKL, OPG | 3-way analysis of variance Tukey’s honest sign diff | Y | NM | RANKL- Inc OPG- Dec | 24 h | avg amt of TM for J > A after 168 h mean vol of GCF in A sign lower than J | GCF vol correl with inflam state | RANKL at 24 h - sign inc levels both in J & A. RANKL and OPG in A < J OPG at 24 h sign dec levels both in J & A. RANKL/OPG for exp T sign > cont after 24 h RANKL/OPG in A < J |
| 31 | IL-2, 6, 8 | 1-way paired | NM | NM | IL-2-inc | IL-2 - 7 d, 21 d of level IL-8 - 7 d of level and 7 d, 21 d of retr | GCF vol greater on 7 d and 21 d of level and retr | NM | IL-8 stat sign dec on 7 d of level |
| IL-6-N change | |||||||||
| IL-8-dec | |||||||||
| 32 | RANKL, OPG | Mann-Whitney U | NM | NM | RANKL - inc OPG - dec | 24 h |
| N sign diff in mean vol of GCF at 24 h b/w exp T and cont T | Mean RANKL values after 24 h in Exp > cont-mean OPG values after 24 h in Exp < cont |
| 33 | IL-1β, SP, PGE2 | Paired | Y | NM | Inc | 1 d | VAS inc sign 1 h and 24 h after insert of sepr and returned to bas after 7 d SP and PGE2 sign higher at 1 d and 7 d | NM | IL-1β of exp > cont at 1 h, 1 d, 7 d |
| 34 | SP, IL-1β | Mann-Whitney U Spearman’s signed rank | NM | NM | Inc | NM | Avg amt of TM was 1.5 ± 0.4 mm over 168 h-N sign diff in tot prot level at any of exp time periods mean SP levels inc after 8, 24, and 72 h in Exp | N sign diff in mean GCF vol b/w exp and cont T | mean IL-1β levels inc after 8, 24, and 72 h in Exp |
| 35 | IL-1β, IL-1RA | ANCOVA | Y | NM | NM | 3 d | Inc lag phase with Mx C moved by 4, 13, and 26 kPa. | Vt vs avg AI in GCF from D sites of Mx C showed a + ve relationship (R2 = 0.44) | mean AI for C moved with 52 kPa sign > all other mean AIs |
| 36 | IL-8 | Mann-Whitney U Wilcoxon | NM | NM | Inc | 6 d at tension site, and 1st 24 h at pressure site | GCF vol greater at tension and pressure sites at 24 h and 30 d | NM | IL-8 at both sites inc at 1 h of F. B/w 24 |
| hand 6 d, inc at tension site. IL-8 inc | |||||||||
| among grps b/w 0 & 1 h stats sign | |||||||||
| 37 | IL-1β, PGE2 | Intra-grp: ANOVA Intergrp: 1-way ANOVA | NM | NM | Inc | 24 h | PGE2 inc at 24 h > BS in CF and IF. PGE2 inc in CF and IF at 24 h > cont In CF,PGE2 > cont at 168 h, then fall. In IF, PGE2 remain high for a wk. | NM | IL-1β inc at 24 h > BS, max at 24 h after 1st act in IF. |
| In IF, IL-1β inc 24 h after 1st reactivn > cont | |||||||||
| In CF and IF, IL-1β inc at 24 h > cont | |||||||||
| 38 | PGE-2, IL-6, GMCSF | Paired | NM | NM | Inc | 24 h | Median GCF vol. in J > A. In J and A PGE2 inc at 24 h > BS | NM | InJ, IL-6, GMCSF inc at 24 h > BS |
| 39 | IL-1β, βG | 1-tailed paired Student | Y | NM | Inc | IL-1β - 81 d βG - 46 d | βG - significantly dec 14 d after prophy. Exp > cont at 46 d | NM | IL-1β significantly dec 14 d after prophy. Exp > cont at 4 d, 33 to 81 d |
| 40 | IL-1β, IL-1RA, AI | Least square regression Pearson product-moment Correl coefficient | NM | NM | Inc | 3 d | C retr at 1.27 and 0.87 mm/m for 13 and 4 kPa of stress, resp | +ve corr of velocity and AI from D > M. | IL-1β at M > Cont (13 kPa) IL-1RA at D > M and Cont (4 and 13 kPa) |
| 41 | TGF-β | Student’s | Y | NM | Inc | 24 h | C retr was 1.1 at 0.1 mm/168 h | NM | TGF-β at exp site at 24 h > bas, Cont |
| 42 | IL-1β, IL-6, TNF-α, EGF, β2-μG | Student’s | Y | NM | Inc | 24 h | β-2 MG inc at 24 h > BS or 1 h | NM | Intra-grp in Exp: IL-1β inc at 24 h > bas, IL-6 inc at 24 h > bas or 168 h, TNF-α inc at 24 h > bas or 168 h, EGF inc at 24 h > bas |
| β-2 MG in exp at 24 h > ant cont | Intergrp btw cont and exp: IL-1β inc in exp > cont at 24 h, mean IL-6 in exp > ant cont, TNF-α in exp at 24 h > ant cont, EGF in exp at 24 h > ant cont | ||||||||
| 19 | IL-1β, PGE | 2-way analy of variance | NM | NM | Inc | 24 h | PGE inc in exp > cont at 24 h, 48 h | NM | IL-1β inc in exp > cont at 1 h, 24 h |
| PGE inc at 24 h > BS, 168 h | IL-1β inc at 24 h > bas, 48 h, 168 h | ||||||||
| 43 | IL-1β, TNF-α, NO | Friedman, Wilcoxon test Spearman Rank Correl Analy. | Y | NM | Inc | 6 m | PI, GI, PD inc at 1 m > BS, 6 m > BS | NM | IL-1β inc at 6 m > bas |
| 44 | RANKL, OPG | Repeated measures ANOVA | NM | NM | Inc | 48 h | PM retr −3.73 ± 1.08 mm (laser grp) and 2.71 ± 0.9 mm (Cont grp) Max mean retr v(t) btw 0 and 48 h. Pain intensity pk at 48 h. | NM | RANKL - inc at 48 h > bas |
| RANKL/OPG - inc at 48 h > bas | |||||||||
| 45 | RANKL, HSP70, | ANOVA | Y | NM | Inc | 24 h | Amylase activity in saliva inc at 24 h at exp > cont | NM | RANKL inc in 24 h > cont |
| 46 | MMP-8, IL-1β | Paired-sample | NM | NM | Inc | 3 m | NM | MMP-8 dec at 24 h, inc at 3 m | IL-1β inc at 3 m |
| 47 | GM-CSF, IF-γ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10 and TNFα, MMP-9, TIMP-1 and 2, RANKL, OPG | Paired non-parametric Kruskall-Wallis. Spearman Rank Sum analy. | Y | NM | Inc | 4 h | +ve corr of GCF vol and plaque index at 0 at(t), (comp) | +ve corr of TNF-α, IL-1β, IL-8, GM-CSF MMP-9 and TIMP levels to speed of OTM at 4 h in Exp corr of IL-1β, IL-8, TNF-α inc to plaque-induced inflam at 0 at (comp). | Exp - IL-1β, IL-8, TNFα inc from 4 h to 42 d. RANKL - inc after 42 d |
| Exp - TIMP 1 and 2 inc at 4 h, 7 d and 42 d, MMP-9 inc at 4 h, 7 d. | |||||||||
| Compr-MMP −9 inc at 4 h and 7 d. TIMP-1 inc at 4 h and TIMP-2 at 7 d. | |||||||||
| Exp > cont: MMP-9 inc at 0, 4 h at compr, TIMP-2 inc at 0 at Exp, compr | |||||||||
| 48 | RANK, OPG, OPN, TGF-β1 | Friedman Dunn’s multiple comparisons as | Y | NM | Inc | 7 d | NM | NM | RANK - inc in 7 d in exp, compres > cont OPG - cont > compres site at 24 h. TGF-β - inc in compres > cont at 7 d. |
| 49 | MMP-3, MMP-9, MMP-13, MIP-1β, MCP-1, RANTES | Friedman, Mann-Whitney | Y | NM | NM | NM | MMPs inc at 1 h, dec at 24 h. GCF vol at (comp) > (t) at 21 d | NM | NM |
| 50 | IL-1β, SP, PGE2 | SPSS 13.0 paired | NM | NM | Inc | 1 d | Exp > Cont: | NM | Exp > Cont: |
| At D, SP inc at 1 d, 7 d | At M, IL-1β inc at 1 min, 1 h, 1 d, 7 d. | ||||||||
| At D, PGE2 inc at 1 min, 1 h, 1 d, 7 d. | At D, IL-1β at 1 h, 1 d, 7 d. | ||||||||
| At M, PGE2, SP, inc at 1 min, 1 h, 1 d, 7 d > BS. | Exp > bas: At M, IL-1β inc at 1 min, 1 h, 1 d, 7 d. At D, IL-1β inc | ||||||||
| At D, SP, PGE2 inc at 1 d, 7 d > BS. | at 1 h, 1 d, 7 d. | ||||||||
| 51 | IL-1β | Wilcoxon signed-rank Mann-Whitney U | NM | NM | Inc | 24 h | IL-1β at 24 h, 48 h at exp > implant | NM | IL-1β inc at 24, 48 h > bas IL-1β dec after 24 h, at 48 h, 168 h, 14 d, 21 d. |
| 52 | IL-2, IL-6, IL-8 | 1-way ANOVA ( interG) Dunnett’s | NM | NM | Inc | 24 h | IL-8 inc at 24 h, 48 h in MS grp | NM | IL-2 inc at 24 h > bas |
| IL-6 inc at 3 m in MS grp | IL-8 inc in Exp at 1 h, 24 h, 48 h | ||||||||
| 53 | CCL-2 (MCP1), CCL-3, CCL-5 (RANTES), IL-8 (CXCL8), IL-1α, IL-1β, IL-6, TNF-α | ANOVA Tukey’s | Y | NM | Inc | 24 h | MOPs inc the rate of C retr by 2.3-fold compd to cont and contr C - VAS sign at 24 h for Exp and Con | MOPs sign inc cyt and chemokine expression | All cyt and chemo inc in both Cont and Exp at 24 h IL-1 inc also at 28 d |
| 54 | TNF-α | Paired | NM | NM | Inc | 24 h | NM | NM | TNF-α inc at 24 h |
| 55 | TNF-α, IL-1β, IL-8 | 1-way ANOVA Paired student t | NM | NM | TNF-α, IL-1β, IL-8 inc in 1 to 2 d of level | 1 d | GCF vol inc in 1 to 3 d of leveling | NM | TNF-α, IL-1β, IL-8 inc in 1 to 2 d of level |
| 56 | IL-1β, IL-1RA, AI | Least square Regression Pearson product-moment Correl coefficient | NM | NM | AI = 1, then v(t) is not zero | NM | C retr at day 84 for 13, 26, 52 kPa were 4.14 ± 0.19, 6.36 ± 1.32, 5.66 ± 1.38 mm resp | v(t) affected by AI in GCF, stress and IL-1 gene cluster | Faster v(t) seen in 26 kPa, higher GCF and allele 1 homozygosity |
| 57 | RANKL, OPG, IL-1, IL-1RA, MMP-9 | Repeated measures models | Y | NM | IL-1/IL-1 + IL-1RA - dec | A - 6 wk | NM | NM | IL-1RA in adults exp > cont at 3 wk. Dec |
| Ado - 3 wk | |||||||||
| 58 | IL-2, IL-4, IL-6, IL-8, IL-10, GM-CSF, IFN-γ, TNF-α, MCP-1, IP-10 | Stepwise regression | NM | NM | NM | NM | NM | IL-6 levels at bas predictive of GCF flows after 1 y of ortho t/t | No sign change |
| 59 | OPG, RANKL | 2-way ANOVA. | NM | NM | OPG inc in M, dec in D at 1 h | 1 h | NM | NM | OPG inc on M, dec in D at 1 h |
Ref No. reference number, Stats statistically, analy analysis, appld applied, Confd confounders, reg regulation, Pk peak, Sec secondary, outcm outcome, correl correlation, sign significant, Y yes, N no, NM not mentioned, inc increase, dec decrease, fluct fluctuated, h hour, m month, tot total, prot protein, conc concentration, mg milligram, ml milliliter, g gram, > greater than, < less than, VAS visual analog scale, C canine, mov movement, b/w between, CF continuous force, IF interrupted force, and and, F force, Assoc associated, gen genetic, GCF gingival crevicular fluid, compd compared, bas baseline, IL interleukin, βG beta glucoronidase, TNF-α tumor necrosis factor alpha, SD short duration, LD long duration, Diff difference, vol volume, retr retraction, correl correlation, inflam inflammation, Avg average, cyt cytokine, chemo chemokine, knwn known, MOPs micro-osteoperforations, PI plaque index, BOP bleeding on probing, exp experimental, cont control, Exp experimental tooth, ant antagonistic, Avg average, Mx maxilla, contr contralateral, differen differentiation, sepr separator, grp group, compres compression, kPa kilopascal, max maximum, grw growth, T tooth, Oc osteoclast, RDG rapid canine distalization group, HG hybrid reactor group. v(t) velocity of tooth movement, M mesial, D distal, level leveling, retr retraction.
CSFs colony-stimulating factors, IFNs interferons, MCSF macrophage colony-stimulating factor, SP substance P, IL-1β interleukin-1 beta, TNF-α tumor necrosis factor-alpha, TGF β transforming growth factor-beta, OPG osteoprotegerin, OPN osteopontin, RANKL receptor activator of nuclear factor kappa-B ligand, RANK receptor activator of nuclear factor kappa-B, GM-CSF granulocyte-macrophage colony-stimulating factor, βG beta glucuronidase, PGE2 prostaglandin E2, IL-1RA interleukin receptor antagonist, MCP monocyte chemoattractant protein, MMP matrix metalloproteinases, MIP macrophage inflammatory protein, TIMP tissue inhibitor of metalloproeintases, HSP heat shock proteins, NO nitric oxide, AI activity index.